What new radiopharma safety and calibration solutions did Mirion Medical unveil at the SNMMI 2025 annual meeting?
Mirion Medical, the healthcare division of global radiation safety leader Mirion Technologies, Inc. (NYSE: MIR), has announced a slate of new radiopharma-focused technologies at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, held June 21–24 in New Orleans, Louisiana. The newly debuted tools aim to expand precision in radiopharmaceutical dosimetry, enhance mobile radiation monitoring, and streamline digital compliance and production workflows for nuclear medicine teams across academic, clinical, and industrial environments.
The American radiation safety innovator is exhibiting its expanded portfolio through its Mirion Medical and Mirion Technologies groups, including new solutions from subsidiaries Capintec and Dosimetry Services. Highlights include the launch of the Graves Phantom for SPECT calibration, the InstadoseVUE Beta dosimeter for theranostic safety, upgrades to the Apex-Guard software platform, and hands-on demonstrations of the ec2 Software Suite used widely in nuclear pharmacy management.
Mirion’s SNMMI 2025 presence affirms its dual commitment to operational precision and patient safety, responding to increasing institutional demand for integrated digital and radiation monitoring systems tailored to complex radiopharma workflows.
How does the Graves Phantom from Capintec improve SPECT calibration and radiopharmaceutical dosimetry?
Capintec, a Mirion Medical company with decades of expertise in medical radiation measurement, introduced the Graves Phantom, a next-generation tissue-equivalent calibration phantom built specifically for radiopharmaceutical therapy (RPT). With a 20-cm design and radioisotope-specific sensitivity calibration capabilities, the device simulates realistic scatter conditions to enable more reproducible and accurate dosimetry workflows in clinical nuclear medicine.
Radiopharmaceutical therapies, including those used in oncology and targeted molecular imaging, require precise measurement of absorbed doses to ensure both safety and therapeutic efficacy. The Graves Phantom helps standardize these measurements by supporting SPECT system calibration and dose validation using known reference conditions.
Experts in nuclear medicine calibration view this development as a key advancement, especially as hospitals and commercial radiopharmacies adopt tighter quality controls to meet expanding regulatory expectations and deliver patient-specific therapy. The system’s reproducibility could reduce clinical variance and support faster deployment of radiolabeled compounds.
In what ways does the InstadoseVUE Beta dosimeter support safety in theranostic environments?
Another major product debut at SNMMI 2025 is the InstadoseVUE Beta Dosimeter, developed by Dosimetry Services, a Mirion Medical company. This device is the first hybrid wireless dosimeter designed specifically for environments involving beta radiation, such as theranostic radiopharmaceuticals that combine imaging and therapeutic properties.
The InstadoseVUE Beta provides real-time wireless radiation exposure data, enabling clinicians and technologists to track dose accumulation during diagnostic or therapeutic procedures involving beta-emitting isotopes. It complements Mirion’s broader line of wireless dosimetry products, now widely used in cancer care and high-energy radiology settings.
Institutional users have emphasized the growing need for tailored personnel monitoring solutions as theranostic applications grow. The InstadoseVUE Beta allows for seamless compliance with occupational safety regulations and enhances confidence in staff protection, especially in outpatient isotope handling facilities and advanced PET/SPECT centers.
What capabilities does the upgraded Apex-Guard software offer for radioisotope quality control and compliance?
Mirion Technologies is also showcasing the latest version of Apex-Guard™, its software platform for gamma spectroscopy and isotope quality analysis. The upgraded platform introduces an advanced impurity analysis module and a patent-pending algorithm for assessing isotope purity through high-resolution gamma spectral readings.
This release aims to address challenges in quality management for isotope production, particularly in radiopharma supply chains involving complex compound synthesis or short half-life isotopes. Apex-Guard’s integration with BioTrax™ QMS—a module within the ec2 Software Suite—enables end-to-end visibility into production integrity, batch-level data handling, and compliance audit trails.
Analysts tracking software uptake in the nuclear medicine sector note rising institutional demand for quality control tools that combine analytical fidelity with workflow integration. By bridging spectroscopy data with regulatory documentation, Apex-Guard supports faster release cycles while ensuring safety thresholds are consistently met.
How does the ec2 Software Suite improve operational and regulatory efficiency for nuclear pharmacies and imaging centers?
Mirion Medical’s ec2 Software Suite remains a cornerstone of its digital strategy, offering modular solutions designed to streamline nuclear medicine operations across the value chain. During SNMMI 2025, the company is conducting live demonstrations of BioTrax™ QMS, NMIS™ (Nuclear Medicine Information System), and BioRx™, its prescription and dose tracking module.
These systems are increasingly critical for clinical and commercial radiopharmacies, where operators must manage short-lived isotopes, tight delivery windows, and complex regulatory requirements. The software allows for end-to-end digital management of inventory, prescriptions, production workflows, and patient-specific tracking, with built-in tools for record-keeping and compliance reporting.
Nuclear medicine departments facing increasing accreditation and audit pressures—particularly under new FDA and NRC oversight structures—have accelerated their transition to digital systems like ec2. Mirion’s interoperable architecture supports customization for academic hospitals, private radiopharmacies, and isotope production labs.
What new mobile radiation monitoring tools did Mirion Technologies introduce for field and clinical use?
Expanding its focus on portability and real-time field monitoring, Mirion Technologies is presenting several mobile radiation detection systems at SNMMI 2025. These include the CSPevo® Probe, the RDS-Med™ Survey Meter, and the IC3™ Portable Ion Chamber Survey Meter. Each is optimized for specific radiation types—gamma, beta, and X-ray—and designed for use in mobile or hospital environments.
The iCAM™ Mobile Alpha/Beta Particulate Monitor, also featured, supports real-time airborne contamination detection. These tools are suited for radiopharma production sites, isotope transport verification, and emergency response teams working in environments with potential contamination risks.
From a clinical safety standpoint, these tools provide additional layers of protection in imaging and therapy departments, enabling fast site checks and supporting post-incident reviews or facility audits.
How is Mirion Medical advancing public education and patient engagement in nuclear medicine?
Reinforcing its public engagement strategy, Mirion Medical is a sponsor of the SNMMI 2025 Patient Education Day, an initiative aimed at informing patients and caregivers about the safety, efficacy, and evolving role of nuclear medicine and theranostics in modern healthcare.
The American radiation safety firm is contributing educational materials, including visual content and simplified guides to radiopharmaceutical therapy. As nuclear imaging becomes more common in cancer screening and therapeutic planning, Mirion’s patient-focused messaging supports broader adoption by demystifying radiation-based interventions.
Institutional observers view this initiative as part of a growing industry trend to expand transparency, especially as patient advocacy groups seek clearer understanding of radiation dose, isotope use, and long-term follow-up care after nuclear interventions.
What is the market outlook for Mirion Technologies and its radiation safety divisions after SNMMI 2025?
Mirion Technologies, Inc. (NYSE: MIR), with its healthcare and nuclear divisions, operates in over 12 countries and employs approximately 2,800 professionals. Institutional sentiment around the radiation technology developer remains cautiously optimistic, with growing demand from healthcare systems, defense, energy, and space agencies.
With an expanding portfolio in cancer therapy support, mobile dosimetry, and nuclear quality assurance, Mirion is well-positioned to benefit from the growth of molecular imaging, targeted radiotherapy, and precision medicine. Analysts expect further geographic expansion, additional regulatory partnerships, and new software modules targeting radiopharma logistics and AI-driven analytics.
Future filings and product extensions are likely as regulatory environments tighten and as global cancer centers push toward more data-integrated therapeutic workflows. Mirion’s visibility at SNMMI 2025 reinforces its role as a full-spectrum technology partner for the global nuclear medicine ecosystem.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
